The companies will continue their collaboration, begun in December 2000, to use Third Wave's Invader technology to develop and commercialize molecular diagnostic tests for infectious diseases.
The original agreement the agreement called for BML to pay Third Wave $3 million up front, and provide $4 million in funding for Invader product development over the next three years. In exchange, Third Wave retained the right to market and sell any products developed under the agreement outside